March 3, 2015

CORONADO, Calif. — The Hydrus II trial is the first randomized controlled trial to show a microinvasive glaucoma surgery device to lower IOP by more than 20% without medications statistically more often than cataract surgery alone at 2 years, according to a speaker.

Furthermore, it is the first MIGS randomized controlled trial to report the effect of a glaucoma device using a “terminal washout” protocol, thus removing the confounding effects of glaucoma medications, Thomas W. Samuelson, MD, said at the annual meeting of the American Glaucoma Society.